Latest Proteasome Stories
CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009.
Researchers at Fox Chase Cancer Center have demonstrated that it might be possible to treat genetic diseases, including some forms of cancer, by "rescuing" the misshapen, useless proteins produced by some mutant genes.
WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer.
Researchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first toResearchers at A*STAR's Institute of Molecular and Cell Biology (IMCB) have become the first to discover and characterize a human protein called Bax-beta (BaxÎ²), which can potentially cause the death of cancer cells and lead to new approaches in cancer treatment. discover and characterize a human protein called Bax-beta (BaxÎ²), which can potentially cause the death of cancer cells and lead to...
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
Lead Oral Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral proteasome inhibitor.
SOUTH SAN FRANCISCO, Oct.
SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the successful completion of a new financing round of $79 million.
Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia.
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients.
- To give a box on the ear to.